HALO
Price
$58.77
Change
-$0.00 (-0.00%)
Updated
Jul 25 closing price
Capitalization
7.18B
8 days until earnings call
XENE
Price
$30.30
Change
-$0.71 (-2.29%)
Updated
Jul 25 closing price
Capitalization
2.33B
11 days until earnings call
Interact to see
Advertisement

HALO vs XENE

Header iconHALO vs XENE Comparison
Open Charts HALO vs XENEBanner chart's image
Halozyme Therapeutics
Price$58.77
Change-$0.00 (-0.00%)
Volume$391
Capitalization7.18B
Xenon Pharmaceuticals
Price$30.30
Change-$0.71 (-2.29%)
Volume$969.94K
Capitalization2.33B
HALO vs XENE Comparison Chart in %
Loading...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HALO vs. XENE commentary
Jul 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HALO is a StrongBuy and XENE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 28, 2025
Stock price -- (HALO: $58.77 vs. XENE: $30.30)
Brand notoriety: HALO and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HALO: 0% vs. XENE: 83%
Market capitalization -- HALO: $7.18B vs. XENE: $2.33B
HALO [@Biotechnology] is valued at $7.18B. XENE’s [@Biotechnology] market capitalization is $2.33B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HALO’s FA Score shows that 1 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • HALO’s FA Score: 1 green, 4 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, HALO is a better buy in the long-term than XENE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HALO’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • HALO’s TA Score: 4 bullish, 6 bearish.
  • XENE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, XENE is a better buy in the short-term than HALO.

Price Growth

HALO (@Biotechnology) experienced а +4.11% price change this week, while XENE (@Biotechnology) price change was -4.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

HALO is expected to report earnings on Aug 05, 2025.

XENE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HALO($7.18B) has a higher market cap than XENE($2.33B). HALO YTD gains are higher at: 22.924 vs. XENE (-22.704). HALO has higher annual earnings (EBITDA): 705M vs. XENE (-290.36M). HALO has more cash in the bank: 748M vs. XENE (550M). XENE has less debt than HALO: XENE (8.68M) vs HALO (1.51B). HALO has higher revenues than XENE: HALO (1.08B) vs XENE (7.5M).
HALOXENEHALO / XENE
Capitalization7.18B2.33B309%
EBITDA705M-290.36M-243%
Gain YTD22.924-22.704-101%
P/E Ratio15.49N/A-
Revenue1.08B7.5M14,453%
Total Cash748M550M136%
Total Debt1.51B8.68M17,372%
FUNDAMENTALS RATINGS
HALO vs XENE: Fundamental Ratings
HALO
XENE
OUTLOOK RATING
1..100
887
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
3750
SMR RATING
1..100
1295
PRICE GROWTH RATING
1..100
5286
P/E GROWTH RATING
1..100
895
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XENE's Valuation (74) in the Biotechnology industry is in the same range as HALO (76). This means that XENE’s stock grew similarly to HALO’s over the last 12 months.

HALO's Profit vs Risk Rating (37) in the Biotechnology industry is in the same range as XENE (50). This means that HALO’s stock grew similarly to XENE’s over the last 12 months.

HALO's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for XENE (95). This means that HALO’s stock grew significantly faster than XENE’s over the last 12 months.

HALO's Price Growth Rating (52) in the Biotechnology industry is somewhat better than the same rating for XENE (86). This means that HALO’s stock grew somewhat faster than XENE’s over the last 12 months.

XENE's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for HALO (89). This means that XENE’s stock grew significantly faster than HALO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HALOXENE
RSI
ODDS (%)
Bearish Trend 3 days ago
63%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
69%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
82%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
75%
Advances
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 11 days ago
72%
Declines
ODDS (%)
Bearish Trend 7 days ago
68%
Bearish Trend 3 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
69%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
63%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MMUCX24.370.06
+0.25%
MFS Utilities C
RGLGX27.020.01
+0.04%
American Funds Global Insight R-6
LMEAX20.07-0.03
-0.15%
Franklin International Equity A
TIRGX17.31-0.03
-0.17%
T. Rowe Price Global Real Estate I
TOLCX16.44-0.05
-0.30%
DWS RREEF Global Infrastructure C

HALO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HALO has been loosely correlated with XENE. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if HALO jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HALO
1D Price
Change %
HALO100%
N/A
XENE - HALO
43%
Loosely correlated
-2.29%
VIR - HALO
40%
Loosely correlated
-1.91%
ARGX - HALO
38%
Loosely correlated
+0.04%
IMCR - HALO
34%
Loosely correlated
-0.28%
IDYA - HALO
33%
Poorly correlated
-1.33%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
-2.29%
IDYA - XENE
59%
Loosely correlated
-1.33%
CRNX - XENE
54%
Loosely correlated
N/A
ATXS - XENE
52%
Loosely correlated
+1.37%
DNLI - XENE
52%
Loosely correlated
-4.47%
NRIX - XENE
51%
Loosely correlated
-0.09%
More